PPT1 and Alzheimer disease: Further, these data imply that the progression of CLN1 may be mediated by the palmitoylation of Fyn kinase, which is also being targeted for the treatment of Alzheimer’s disease (Kaufman et al., 2015; Nygaard et al., 2015).